IMPACT OF INITIATING LONG-ACTING INJECTABLES ON ALL-CAUSE AND PSYCHIATRIC HOSPITALIZATION IN PATIENTS WITH BIPOLAR I DISORDER
Author(s)
Greene M1, Yan T2, Chang E2, Touya M3
1Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA, 2Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 3Lundbeck LLC, Deerfield, IL, USA
OBJECTIVES: To compare risk of all-cause and psychiatric hospitalization in patients with bipolar I disorder (BP-I) initiating different long-acting injectable antipsychotics (LAIs). METHODS: This retrospective study used data from three distinct Truven Health Analytics MarketScan® databases including individuals with Medicaid, Commercial, and Medicare supplemental insurance. The study cohorts were comprised of patients ≥18 years old with BP-I during the study period (1/1/12-6/30/16) who started one of the following available LAIs during the identification period (1/1/2013-6/30/15): aripiprazole once-monthly (AOM 400), fluphenazine-LAI, haloperidol-LAI, risperidone-LAI, and paliperidone-4-week-LAI. The index date was defined as the earliest occurrence (the first date) of a claim for one of the LAI therapies of interest during the ID period. Multivariate logistic regression models were conducted to estimate risk of hospitalization, adjusting for demographic and clinical characteristics, insurance type, baseline medication, and baseline hospitalization. RESULTS: Of the identified patients with BP-I, 413 initiated AOM 400, 154 fluphenazine-LAI, 476 haloperidol-LAI, 1,026 paliperidone-LAI, and 323 risperidone-LAI. Adjusting for differences in baseline characteristics, the odds of having both all-cause and psychiatric hospitalization during the 1-year post-index period were significantly higher in the haloperidol-LAI [Odds ratio (OR) (95% CI): 1.39 (1.03 – 1.87) (all-cause), p=0.029; 1.41 (1.03 – 1.93) (psychiatric-specific), p=0.010] and risperidone-LAI [1.54 (1.12 - 2.13), p=0.009; 1.68 (1.20 - 2.37), p=0.003] cohorts compared with AOM 400 users. The fluphenazine-LAI and paliperidone-LAI users also had higher risk of hospitalization compared with AOM 400 users, but the differences were not statistically significant (p>0.05). Across LAIs, AOM 400 users had the lowest adjusted psychiatric (25.7%; p=0.013) hospitalization rate. CONCLUSIONS: This study suggests that AOM 400 may be more beneficial at reducing the risk of both all-cause and psychiatric hospitalization in patients with BP-I in a real-world setting as compared to haloperidol-LAI and risperidone-LAI.
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Value in Health, Vol. 21, S1 (May 2018)
Code
PMH56
Topic
Economic Evaluation, Health Service Delivery & Process of Care
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Prescribing Behavior
Disease
Mental Health